NO122090B - - Google Patents
Download PDFInfo
- Publication number
- NO122090B NO122090B NO0736/68A NO73668A NO122090B NO 122090 B NO122090 B NO 122090B NO 0736/68 A NO0736/68 A NO 0736/68A NO 73668 A NO73668 A NO 73668A NO 122090 B NO122090 B NO 122090B
- Authority
- NO
- Norway
- Prior art keywords
- insulin
- solution
- added
- bovine
- weight
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 90
- 239000000243 solution Substances 0.000 claims description 62
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 39
- 108090001061 Insulin Proteins 0.000 claims description 38
- 102000004877 Insulin Human genes 0.000 claims description 38
- 229940125396 insulin Drugs 0.000 claims description 38
- 101001011741 Bos taurus Insulin Proteins 0.000 claims description 33
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 claims description 33
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims description 32
- 239000011701 zinc Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 230000007935 neutral effect Effects 0.000 claims description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 9
- 229910052725 zinc Inorganic materials 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 239000001488 sodium phosphate Substances 0.000 claims description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 239000003755 preservative agent Substances 0.000 description 10
- 108010005991 Pork Regular Insulin Proteins 0.000 description 9
- 238000001556 precipitation Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000002335 preservative effect Effects 0.000 description 5
- 235000015278 beef Nutrition 0.000 description 4
- 239000012064 sodium phosphate buffer Substances 0.000 description 4
- 101000993800 Sus scrofa Insulin Proteins 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 229940048914 protamine Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- -1 insulin compound Chemical class 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108010066090 neutral insulin Proteins 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C07K14/625—Extraction from natural sources
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK107567AA DK116527B (da) | 1967-03-01 | 1967-03-01 | Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO122090B true NO122090B (OSRAM) | 1971-05-18 |
Family
ID=8100713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO0736/68A NO122090B (OSRAM) | 1967-03-01 | 1968-02-28 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US3584121A (OSRAM) |
| BE (1) | BE711554A (OSRAM) |
| CH (1) | CH561066A5 (OSRAM) |
| DE (1) | DE1667900C3 (OSRAM) |
| DK (1) | DK116527B (OSRAM) |
| FR (1) | FR1556052A (OSRAM) |
| GB (1) | GB1222100A (OSRAM) |
| NL (1) | NL157208B (OSRAM) |
| NO (1) | NO122090B (OSRAM) |
| SE (1) | SE385769B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56147751A (en) * | 1980-02-29 | 1981-11-16 | Hospital For Sick Children | Polypeptide disaggregation solution |
| DE3013912A1 (de) * | 1980-04-11 | 1981-10-29 | Röhm GmbH, 6100 Darmstadt | Polymerprodukte zur behandlung von bloessen und leder |
| FI78616C (fi) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
| ES8403723A1 (es) * | 1982-03-03 | 1984-04-16 | Nordisk Insulinlab | Procedimiento de producir preparaciones de insulina. |
| DE69019534T2 (de) * | 1989-12-21 | 1995-09-21 | Novonordisk As | Insulinzubereitungen, die nikotinsäure oder nikotinamid enthalten. |
| EP0921812B2 (en) * | 1996-06-20 | 2011-12-21 | Novo Nordisk A/S | Insulin preparations containing a halogenide |
| TW201630622A (zh) | 2014-12-16 | 2016-09-01 | 美國禮來大藥廠 | 速效胰島素組合物 |
-
1967
- 1967-03-01 DK DK107567AA patent/DK116527B/da not_active IP Right Cessation
-
1968
- 1968-02-28 NO NO0736/68A patent/NO122090B/no unknown
- 1968-02-28 US US708942A patent/US3584121A/en not_active Expired - Lifetime
- 1968-02-28 GB GB9646/68A patent/GB1222100A/en not_active Expired
- 1968-02-28 NL NL6802798.A patent/NL157208B/xx unknown
- 1968-02-29 CH CH296568A patent/CH561066A5/xx not_active IP Right Cessation
- 1968-03-01 FR FR1556052D patent/FR1556052A/fr not_active Expired
- 1968-03-01 BE BE711554D patent/BE711554A/xx not_active IP Right Cessation
- 1968-03-01 SE SE6802680A patent/SE385769B/xx unknown
- 1968-03-01 DE DE1667900A patent/DE1667900C3/de not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| GB1222100A (en) | 1971-02-10 |
| NL6802798A (OSRAM) | 1968-09-02 |
| DK116527B (da) | 1970-01-19 |
| NL157208B (nl) | 1978-07-17 |
| FR1556052A (OSRAM) | 1969-01-31 |
| DE1667900A1 (de) | 1972-01-05 |
| SE385769B (sv) | 1976-07-26 |
| DE1667900C3 (de) | 1982-10-21 |
| DE1667900B2 (de) | 1974-03-07 |
| US3584121A (en) | 1971-06-08 |
| CH561066A5 (OSRAM) | 1975-04-30 |
| BE711554A (OSRAM) | 1968-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BOGDANSKI et al. | The effects of inorganic ions on the storage and uptake of H3-norepinephrine by rat heart slices | |
| Pletscher et al. | New aspects on the storage of 5-hydroxytryptamine in blood platelets | |
| US4585735A (en) | Prolonged storage of red blood cells | |
| Lorenz et al. | Histamine release in human subjects by modified gelatin (Haemaccel) and dextran: an explanation for anaphylactoid reactions observed under clinical conditions? | |
| Edwards et al. | In vivo changes of cerebral cyclic adenosine 3′, 5′‐monophosphate induced by biogenic amines: association with phosphorylase activation | |
| DE69308673T2 (de) | Lösung zur Verwendung bei der Transplantation von Organen | |
| NO161204B (no) | Fremgangsmaate for fremstilling av en insulinopploesning. | |
| US4472385A (en) | Stabilized insulin preparations and method for their production | |
| Bhattacharyya et al. | Stabilization of microtubules by lithium ion | |
| JP2018521027A (ja) | 周囲温度または亜正常温度での組織保存のための組成物および方法 | |
| EP1362511B1 (de) | Protektive Lösung zur Verhinderung von Ischämieschäden | |
| Pfeiffer et al. | Reserpine-induced gastric ulcers: protection by lysosomal stabilization due to zinc | |
| NO122090B (OSRAM) | ||
| KR880013572A (ko) | 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도 | |
| EP1476014B1 (en) | Process for preserving cells, tissues and organs | |
| WO1986000812A1 (en) | A drug kit or drug composition for use in preventing and treating ischaemic cell damage and preparation thereof | |
| Keller et al. | Evidence for in vivo light-induced synthesis of ribulose-1, 5-diP carboxylase and phosphoribulokinase in greening barley leaves | |
| Whittam et al. | Effects of the freeze-thaw process on α amylase | |
| Brodkin et al. | Binding of acetylcholine | |
| JP4931035B2 (ja) | 細胞・組織の凍結障害防止液及び凍結保存法 | |
| DE69517806T2 (de) | Stabile wässrige folinatlösung | |
| Nishimura et al. | Exocytotic secretion of catecholamines from the cat adrenal medulla by sodium deprivation: involvement of calcium influx mechanism | |
| ES2048263T3 (es) | Composicion liofilizada de mdm y metodo para su fabricacion. | |
| Kay et al. | Effects of phenobarbitone, cinnarizine, and zoxazolamine on the development of right ventricular hypertrophy and hypertensive pulmonary vascular disease in rats treated with monocrotaline | |
| US2266992A (en) | Therapeutic composition |